TabletsClinical Overview
Rivaroxaban is an oral, direct, and selective competitive factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. By blocking factor Xa, it interrupts both intrinsic and extrinsic coagulation cascades, preventing thrombin generation and clot propagation. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and CAD/PAD risk reduction (in combination with aspirin).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Doses of 15 mg and 20 mg MUST be taken with food/a meal to ensure complete absorption (food increases bioavailability from 66% to near 100%). Doses of 2.5 mg and 10 mg can be taken with or without food. Do not miss doses.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Bleeding, epistaxis, hematoma, gastrointestinal hemorrhage, dizziness, headache. Rare/Severe: Boxed warnings: Increased thrombotic events on premature discontinuation; epidural/spinal hematoma with neuroaxial procedures; major fatal hemorrhage.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warnings for stroke risk upon premature discontinuation and spinal hematoma during epidural procedures. 15 mg and 20 mg tablets must be taken with meals. Contraindicated in active bleeding and clinically significant hepatic disease. Avoid in moderate-to-severe mitral stenosis or mechanical prosthetic heart valves.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Rivaroxaban Tablets 20mg
Rivaroxaban is an oral, direct, and selective competitive factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. By blocking factor Xa, it interrupts both intrinsic and extrinsic coagulation cascades, preventing thrombin generation and clot propagation. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and CAD/PAD risk reduction (in combination with aspirin).
Rivaroxaban Tablet 15 mg
Rivaroxaban is an oral, direct, and selective competitive factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. By blocking factor Xa, it interrupts both intrinsic and extrinsic coagulation cascades, preventing thrombin generation and clot propagation. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and CAD/PAD risk reduction (in combination with aspirin).
Rivaroxaban Tablet 2.5 mg
Rivaroxaban is an oral, direct, and selective competitive factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. By blocking factor Xa, it interrupts both intrinsic and extrinsic coagulation cascades, preventing thrombin generation and clot propagation. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and CAD/PAD risk reduction (in combination with aspirin).